Herceptin shows biosimilar markets can work. To what extent is the question.

Has the promise of biosimilars been fulfilled?

Authors of a case study appearing in this month’s edition of Health Affairs call it “the best example to date” that biosimilars can successfully bring competition to biologic markets. But the researchers aren’t ready to declare the biosimilar debate over, as the real test will come when more copies of megablockbuster Humira arrive on the market.